This study states that Thoracic endovascular aortic repair (TEVAR) of proximal aortic arch disease provides a less invasive treatment option for high-risk patients ineligible for open arch reconstruction. However, the fiscal impact of these techniques remains unclear. Therefore, our objective was to characterize the midterm outcomes after zone 0 and zone 1 TEVAR and to describe the associated technical costs, revenues, and net margins at a single tertiary medical center. In this review We examined all patients who underwent TEVAR between April 2011 and August 2019 through retrospective chart review. Patients were categorized by proximal endograft extent to identify zone 0 or zone 1 repairs. Procedural characteristics and outcomes were described. Technical costs, revenues, and margins were obtained from the hospital finance department. We identified 10 patients (6 zone 0, 4 zone 1) who were denied open arch reconstruction. Patients were predominantly female (n = 8 [80%]), and the mean age was 72.8 ± 5.5 years. Repair was performed in five asymptomatic patients, urgently in three symptomatic patients, and emergently in two ruptured patients.
Reference link- https://www.jvascsurg.org/article/S0741-5214(20)31453-1/fulltext
